Published in Thorax on August 01, 2010
Survival Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) | NCT00268216
Loss of Lung Health from Young Adulthood and Cardiac Phenotypes in Middle Age. Am J Respir Crit Care Med (2015) 1.49
Safety of indacaterol in the treatment of patients with COPD. Int J Chron Obstruct Pulmon Dis (2011) 1.19
Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint ICS/NCCP (I) recommendations. Lung India (2013) 1.13
Efficacy and safety of 4 weeks' treatment with combined fluticasone furoate/vilanterol in a single inhaler given once daily in COPD: a placebo-controlled randomised trial. BMJ Open (2012) 1.13
Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis. Respir Res (2013) 1.12
Analysis of comorbid factors that increase the COPD assessment test scores. Respir Res (2014) 1.06
The association between COPD and heart failure risk: a review. Int J Chron Obstruct Pulmon Dis (2013) 1.06
Managing comorbidities in COPD. Int J Chron Obstruct Pulmon Dis (2015) 1.03
The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2013) 0.95
Predictors of ICS/LABA prescribing in COPD patients: a study from general practice. BMC Fam Pract (2014) 0.92
Comparative efficacy of indacaterol in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis (2012) 0.89
New clinical insights into chronic obstructive pulmonary disease and their implications for pharmacoeconomic analyses. Pharmacoeconomics (2012) 0.86
A clinical in-hospital prognostic score for acute exacerbations of COPD. Respir Res (2014) 0.85
Which patients with chronic obstructive pulmonary disease benefit from the addition of an inhaled corticosteroid to their bronchodilator? A cluster analysis. BMJ Open (2013) 0.85
Chronic obstructive pulmonary disease in China: the potential role of indacaterol. J Thorac Dis (2013) 0.83
Mortality among subjects with chronic obstructive pulmonary disease or asthma at two respiratory disease clinics in Ontario. Can Respir J (2011) 0.78
Lung function and heart disease in American Indian adults with high frequency of metabolic abnormalities (from the Strong Heart Study). Am J Cardiol (2014) 0.78
One-year safety and efficacy study of arformoterol tartrate in patients with moderate to severe COPD. Chest (2014) 0.76
Club Cell-16 and RelB as Novel Determinants of Arterial Stiffness in Exacerbating COPD Patients. PLoS One (2016) 0.75
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Ectopic fat accumulation in patients with COPD: an ECLIPSE substudy. Int J Chron Obstruct Pulmon Dis (2017) 0.75
LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis. Int J Chron Obstruct Pulmon Dis (2017) 0.75
Efficacy and safety of fluticasone furoate/vilanterol or tiotropium in subjects with COPD at cardiovascular risk. Int J Chron Obstruct Pulmon Dis (2015) 0.75
Cardiovascular outcomes with an inhaled beta2-agonist/corticosteroid in patients with COPD at high cardiovascular risk. Heart (2017) 0.75
Therapeutic effects of the combination of inhaled beta2-agonists and beta-blockers in COPD patients with cardiovascular disease. Heart Fail Rev (2017) 0.75
Clinical assessment of endothelial function in patients with chronic obstructive pulmonary disease: a systematic review with meta-analysis. Intern Emerg Med (2017) 0.75
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2007) 47.86
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med (2012) 22.96
Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med (2007) 19.86
A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med (2008) 17.19
Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med (2010) 15.07
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97
Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 7.67
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med (2008) 6.17
Changes in forced expiratory volume in 1 second over time in COPD. N Engl J Med (2011) 5.69
American Thoracic Society/European Respiratory Society statement on pulmonary rehabilitation. Am J Respir Crit Care Med (2006) 5.65
Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res (2010) 5.17
Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J (2013) 4.65
Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med (2010) 4.19
Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J Med (2015) 4.16
GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med (2012) 3.98
Airway wall thickening and emphysema show independent familial aggregation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 3.70
C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2006) 3.69
Six-minute-walk test in chronic obstructive pulmonary disease: minimal clinically important difference for death or hospitalization. Am J Respir Crit Care Med (2012) 3.44
What is chronic obstructive pulmonary disease anyway?: Continua, categories, cut points, and moving beyond spirometry. Am J Respir Crit Care Med (2013) 3.39
Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. Am J Respir Crit Care Med (2012) 3.09
Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study. J Am Coll Cardiol (2013) 3.03
Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med (2012) 3.00
FAQs about the GOLD 2011 assessment proposal of COPD: a comparative analysis of four different cohorts. Eur Respir J (2013) 2.87
Single maintenance and reliever therapy (SMART) of asthma: a critical appraisal. Thorax (2010) 2.86
Determinants of depression in the ECLIPSE chronic obstructive pulmonary disease cohort. Am J Respir Crit Care Med (2010) 2.80
Development and Validation of an Improved, COPD-Specific Version of the St. George Respiratory Questionnaire. Chest (2007) 2.67
Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. JAMA (2013) 2.59
'Highlights from this issue’ in the November issue of Thorax. Thorax (2013) 2.59
Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One (2012) 2.52
Long-term outcome after ICD and CRT implantation and influence of remote device follow-up: the ALTITUDE survival study. Circulation (2010) 2.45
Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest (2003) 2.44
Gene expression profiling of human lung tissue from smokers with severe emphysema. Am J Respir Cell Mol Biol (2004) 2.33
Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study. Respir Res (2009) 2.31
Brain structure and function in chronic obstructive pulmonary disease: a multimodal cranial magnetic resonance imaging study. Am J Respir Crit Care Med (2012) 2.27
Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 2.21
Prevalence and progression of osteoporosis in patients with COPD: results from the TOwards a Revolution in COPD Health study. Chest (2009) 2.20
Smoking reduction, smoking cessation, and mortality: a 16-year follow-up of 19,732 men and women from The Copenhagen Centre for Prospective Population Studies. Am J Epidemiol (2002) 2.16
Standardizing measurement of chronic obstructive pulmonary disease exacerbations. Reliability and validity of a patient-reported diary. Am J Respir Crit Care Med (2010) 2.09
Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax (2007) 2.05
Variability of a closed, rebreathing setup for multiple breath wash-out testing in children. Pediatr Pulmonol (2012) 2.03
Health status assessment in routine clinical practice: the chronic obstructive pulmonary disease assessment test score in outpatients. Respiration (2012) 1.99
Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.99
A genome-wide association study of COPD identifies a susceptibility locus on chromosome 19q13. Hum Mol Genet (2011) 1.98
Cardiac resynchronization therapy and the relationship of percent biventricular pacing to symptoms and survival. Heart Rhythm (2011) 1.93
Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial. Respir Res (2011) 1.89
Combination bronchodilator therapy in the management of chronic obstructive pulmonary disease. Respir Res (2013) 1.86
Current controversies and future perspectives in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2011) 1.79
A pooled analysis of FEV1 decline in COPD patients randomized to inhaled corticosteroids or placebo. Chest (2007) 1.79
Heart failure decompensation and all-cause mortality in relation to percent biventricular pacing in patients with heart failure: is a goal of 100% biventricular pacing necessary? J Am Coll Cardiol (2009) 1.79
Biologic lung volume reduction in advanced upper lobe emphysema: phase 2 results. Am J Respir Crit Care Med (2009) 1.78
Genome-wide association analysis of blood biomarkers in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2012) 1.72
Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease. Thorax (2012) 1.72
Identification of five chronic obstructive pulmonary disease subgroups with different prognoses in the ECLIPSE cohort using cluster analysis. Ann Am Thorac Soc (2015) 1.72
Real world evaluation of dual-zone ICD and CRT-D programming compared to single-zone programming: the ALTITUDE REDUCES study. J Cardiovasc Electrophysiol (2011) 1.69
Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the ECLIPSE cohort. Eur Respir J (2013) 1.66
Chronic obstructive pulmonary disease biomarker(s) for disease activity needed--urgently. Am J Respir Crit Care Med (2010) 1.66